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Interleukin-2 (IL-2) transgenic Ewing sarcoma cells can induce tumor specific T and NK 
cell responses and reduce tumor growth in vivo and in vitro. Nevertheless, the efficiency 
of this stimulation is not high enough to inhibit tumor growth completely. In addition to rec-
ognition of the cognate antigen, optimal T-cell stimulation requires signals from so-called 
co-stimulatory molecules. Several members of the tumor necrosis factor superfamily 
have been identified as co-stimulatory molecules that can augment antitumor immune 
responses. OX40 (CD134) and OX40 ligand (OX40L = CD252; also known as tumor 
necrosis factor ligand family member 4) is one example of such receptor/ligand pair with 
co-stimulatory function. In the present investigation, we generated OX40L transgenic 
Ewing sarcoma cells and tested their immunostimulatory activity in vitro. OX40L trans-
genic Ewing sarcoma cells showed preserved expression of Ewing sarcoma-associated 
(anti)gens including lipase member I, cyclin D1 (CCND1), cytochrome P450 family mem-
ber 26B1 (CYP26B1), and the Ewing sarcoma breakpoint region 1-friend leukemia virus 
integration 1 (EWSR1-FLI1) oncogene. OX40L-expressing tumor cells showed a trend 
for enhanced immune stimulation against Ewing sarcoma cells in combination with IL-2 
and stimulation of CD137. Our data suggest that inclusion of the OX40/OX40L pathway 
of co-stimulation might improve immunotherapy strategies for the treatment of Ewing 
sarcoma.
Keywords: ewing sarcoma, immunotherapy, co-stimulation, OX40/OX40l system, tumor necrosis factor (receptor) 
superfamily
inTrODUcTiOn
Ewing sarcomas (or “Ewing family tumors,” EFT) represent bone and/or soft-tissue tumors of 
uncertain histogenetic origin. The majority of the cases are observed in children and young adults. 
Today, more than half of the patients with localized EFT can be cured. However, the prognosis for 
patients with disseminated disease or early relapses remains poor with conventional therapy (1). 
EFTs are characterized by the expression of tumor-specific oncofusion proteins (2). These fusion 
proteins are highly tumor specific and might be interesting targets for immunological treatment 
strategies. However, peptides derived from these proteins have only low binding affinity to common 
human leukocyte antigen (HLA) class I molecules (3). Using high-density DNA microarrays, we 
identified additional potential tumor antigens expressed in EFT (4–7). The presence of such tumor-
specific antigens alone is not sufficient for the induction of efficient immune responses. Additional 
co-stimulatory signals are required. We demonstrated that interleukin-2 (IL-2) transgenic EFT cells 
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can induce immune responses against wild-type tumor cells 
in  vitro and in a xenotransplantation model (8–10). However, 
tumor growth was not completely inhibited in this model, sug-
gesting that additional co-stimulatory signals might be required. 
One group of such co-stimulatory molecules is represented by 
members of the tumor necrosis factor (TNF) superfamilies (SF) 
consisting of the superfamily of TNF receptors (TNFRSF) and the 
corresponding ligands (TNFSF). The eponymic member of the 
TNFSF has been initially characterized as a factor with antitumor 
activity in mice (11). TNF is the prototype of a large gene family, 
which has several immune-regulatory functions and can augment 
antitumor immune responses (12, 13). Members of the tumor 
necrosis factor receptor superfamily comprise a group of type I 
membrane glycoproteins consisting of more than 50 members 
that have been identified as co-stimulatory molecules that aug-
ment antitumor immune responses. Activation of these surface 
receptors by the natural ligands or by agonistic antibodies leads 
to different cellular responses ranging from cell differentiation, 
proliferation, apoptosis, and survival to enhanced production of 
cytokines and chemokines (13–16). The differential and unique 
expression of the TNFRSF molecules on cells of the immune 
system has made these molecules as ideal targets for new immune 
therapy strategies (13, 15). OX40 (CD134) and CD137 (4-1BB) 
and their ligands OX40L (CD252) and 4-1BBL are examples of 
such co-stimulatory molecules. CD137 (4-1BB) is an activation-
inducible TNFRSF member expressed on activated T cells 
(CD8-positive and CD4-positive T cells) and is also expressed 
on a variety of immune cell lineages including activated natural 
killer cells, human macrophages, eosinophils, and dendritic cells 
(17). The natural ligand for CD137 (4-1BBL) is mostly expressed 
on professional antigen-presenting cells or in inflamed non-
hematopoietic tissues (15).
Recently, we analyzed the effects of the CD137/4-1BBL system 
in our Ewing sarcoma immune-therapy model (10). 4-1BBL 
transgenic cells or agonistic antibodies against CD137 can 
induce rejection of varying tumors in vivo (18, 19). In our Ewing 
sarcoma model, we observed modulation of immunosuppressive 
indoleamine 2,3-dioxygenase 1 (IDO) expression by stimulation 
of the CD137/4-1BBL system (10). However, engagement of this 
co-stimulatory system had only limited efficacy for enhancing the 
immunostimulatory activity of EFT cells (10). The OX40/OX40L 
system represents another highly interesting co-stimulatory 
system. OX40 (CD134) was identified as cell surface molecule 
on activated T cells (20). OX40 is preferentially expressed on 
CD4-positive T cells (21–23). Optimal antigenic stimulation 
induces OX40 expression also on CD8-positive T cells (24). The 
human OX40 molecule has a molecular weight of 50 kDa and is 
encoded on chromosome 1p36. Murine and human OX40 have 
only approximately 62% sequence homology in the intracellular 
domain and <64% in the extracellular domain (25, 26). OX40 
is absent from unstimulated peripheral blood mononuclear cells 
(PBMCs) and most antigen-presenting cells (27). OX40 expres-
sion peaks 48 h after stimulation of naive T cells, whereas memory 
T cells express high levels 4 h after restimulation (28). In contrast 
to the OX40 receptor, the ligand OX40L (CD252, TNFSF4) is 
expressed on several professional antigen-presenting cell types, 
endothelial cells, and activated T cells (29–32). Human OX40L 
has a molecular weight of 34 kDa and is located on chromosome 
1q25 (25, 26). Activation of the OX40 receptor by OX40L or an 
agonistic antibody leads to increased expression of antiapoptotic 
molecules and reduced expression of the inhibitory cytotoxic 
T-lymphocyte antigen 4 (CTLA4) (25, 33, 34). An important 
aspect of OX40 for antitumor immune responses is the observa-
tion that the OX40/OX40L system favors the development of 
tumor-specific memory T cells and T cells expressing OX40 have 
been found in tumor-draining lymph node cells and in tumor-
infiltrating lymphocytes from patients with various tumors (15, 
35). In addition, direct enhancement of cytotoxic T cells by OX40 
stimulation has been proposed (36). Therefore, in the present 
investigation, we established OX40L overexpressing Ewing sar-
coma cells for analyzing the effects of OX40 stimulation in our 
immunotherapy model.
MaTerials anD MeThODs
gene expression analysis and cloning of 
OX40l
RNA from cell lines was isolated using TRIzol reagent (Invitrogen, 
Karlsruhe, Germany) following manufacturer’s protocol. Two 
micrograms of the RNA was transcribed into cDNA and used as 
template for polymerase chain reaction (PCR). Reverse transcrip-
tion of RNA was performed by using the following conditions: 
4  μL 5× buffer, 1  μL Oligo-dT12-18 primer, 1  μL dNTP mix 
(10  mM), 1  μL Revert Aid H-M-MuLV reverse transcriptase 
(Fermentas, St. Leon Rot, Germany); 37°C, 60  min; and 90°C, 
5 min. After reverse transcription, 2 μL cDNA was mixed with 
2.5 μL 10× buffer, 1.5 μL MgCl2 (25 mM), 0.2 μL Taq-polymerase 
(Promega, Mannheim, Germany), 0.5 μL dNTP mix (10  mM; 
Fermentas), 0.25 μL of sequence specific primers (MWG-Biotech 
AG, Ebersberg, Germany), and 17.8  μL water. The following 
primer combinations were used: actin beta (ACTB): 5′-GGC 
ATC GTG ATG GAC TCC G-3′ and 5′-GCT GGA AGG TGG 
ACA GCG A-3′; cyclin D1 (CCND1): 5′-AAC TAC CTG GAC 
CGC TTC CT-3′ and 5′-CCA CTT GAG CTT GTT CAC CA-3′; 
CD99: 5′-TCC TCC GGT AGC TTT TCA GA-3′ and 5′-TCC 
CCT TGT TCT GCA TTT TC-3′; OX40L (primer combination 
1): 5′-aac tcg agT ATC GCA CGT TCC CCT T-3′ (nucleotides 
in lower case: XhoI restriction site) and 5′-aac cgc ggC CAG 
GAT CTG CTT-3′ (nucleotides in lower case: SacII restriction 
site); OX40L (primer combination 2): 5′-GTG AAT GGC GGA 
GAA CTG AT-3′ and 5′-GCC AGG ATC TGC TTC TTG TC-3′; 
cytochrome P450 26B1 (CYP26B1): 5′-TGA CAG GAT CCC 
TGT GTT GT-3′ and 5′-CCA ACA TCG AAA GTG CTT CA-3′; 
enhanced green fluorescent protein (eGFP): 5′-ACG TAA ACG 
GCC ACA AGT TC-3′ and 5′-AAG TCG TGC TGC TTC ATG 
TG-3′; Janus kinase 1 (JAK1): 5′-TGT AAG GAG CTG GCT GAC 
CT-3′ and 5′-CAC CTG CTC CCC TGT ATT GT-3′; lipase H 
(LIPH): 5′-GAT GGC TGG GGA GAA TTA CA-3′ and 5′-TGG 
ATT CTG TGG TGT TTC CA-3′; lipase I (LIPI): 5′-TCC GAG 
AAT AGA GAC CAT TCT GA-3′ and 5′-GCT CTC TGG TGG 
TTG CAT TT-3′; neomycin resistance cassette (NeoR): 5′-AGA 
CAA TCG GCT GCT CTG AT-3′ and 5′-AGT GAC AAC GTC 
GAG CAC AG-3′. The PCR conditions were as follows: 94°C, 
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30 s; 60°C, 45 s; and 72°C, 45 s (35 cycles). Each PCR program 
started with a denaturation step (95°C, 5 min) and was finished 
with 72°C for 5 min followed by cooling down to 4°C. The PCR 
products were subjected to agarose gel (1.5%) electrophoresis in 
the presence of ethidium bromide. DNA microarray data were 
visualized by using Genesis (37). DNA microarray data from EFT 
cell lines (4, 38), human embryonic kidney 293 (HEK293) cells 
(39), neuroblastoma (NB) cell lines (4), acute lymphatic leukemia 
(ALL) cell lines (40, 41), acute myeloid leukemia (AML) cell lines 
(42), Hodgkin’s lymphoma (HL) cell lines (43), Epstein–Barr 
virus-immortalized lymphoblastoid cell lines (LCL) (44), and 
normal PBMCs (45) were used. For cloning of OX40L, cDNA 
was amplified by using the OX40L primer combination 1. PCR 
products and vector pIRES2-eGFP (Clontech, Mountain View, 
CA, USA) were digested with XhoI and SacII. After agarose gel 
purification, ligation, and transformation into Escherichia coli 
XL1-Blue, individual clones were sequenced by using primers 
5′-CAA GTC TCC ACC CCA TTG AC-3′, 5′-GTG AAG ATG 
GAA AGG GTC CA-3′, 5′-aac cgc ggC CAG GAT CTG CTT-3′, 
and 5′-CAG GGC ATG GAT TCT TCA TT-3′. For sequencing, 
a 10 μL sequencing mix was used that contained 0.5 μL gene-
specific sequencing primers (10 μM), 4.0 μL BigDyeTerminator 
Cycle Sequencing Kit mix (Applied Biosystems, Foster City, CA, 
USA), and 10–30  ng DNA. Sequence analysis was performed 
using ABI Prism™ 310 Genetic Analyzer (Applied Biosystems). 
A clone with complete error-free OX40L open reading frame was 
used for further analysis. This clone differs from the reference 
sequence by a T to C transition in the 3′-untranslated region (cor-
responding to residue 738 in reference sequence NM_003326).
cells and cell culture
A673 cells and HEK293 cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA). SK-N-MC cells 
and SH-SY5Y cells were obtained from the Deutsche Sammlung 
für Mikroorganismen und Zellkulturen (Brunswick, Germany). 
4-1BBL transgenic A673 cells and stimulation of PBMCs with 
anti-CD137 antibodies (clone 26G6; a kind gift from R. Mittler) 
was described elsewhere (10). PBMCs were isolated from healthy 
donors with informed consent and approval by the local ethics 
committee as described (45). Cells were cultured in RPMI-1640 
medium supplemented with 10% fetal calf serum and penicillin 
and streptomycin. For selection of transgenic cells, medium was 
supplemented with 400 μg/mL geneticin sulfate. PBMCs from 
HLA-A1,A2 positive donors were isolated as described (44, 
45). Stimulation of PBMCs and enzyme-linked immunospot 
(ELISPOT) analysis was performed as described (7) by using an 
interferon gamma ELISPOT kit (Becton-Dickinson, Heidelberg, 
Germany). Transfection of cells was performed using jet PEI 
(Qbiogene, Carlsbad, CA, USA). MACS separation was per-
formed using anti-PE microbeads (Miltenyi, Bergisch Gladbach, 
Germany). Statistical analysis was performed with Microsoft 
Excel 2010 (Microsoft, Redmond, WA, USA).
Flow cytometry
Phycoerythrin (PE)-labeled mouse anti-human-OX40L antibod-
ies were purchased from Anzell (Bayport, USA). Mouse IgG1 
isotype control was purchased from Becton-Dickinson. Flow 
cytometry was performed as described (40), and cells were 
analyzed on a FACScan flow cytometer (Becton-Dickinson) 
equipped with CellQuest Pro software (Becton-Dickinson).
resUlTs
cloning of OX40l into a Mammalian 
expression Vector
We screened DNA microarray data of varying cell types for 
samples with high expression of OX40L. Highest expression 
was observed in lymphoblastoid B cell lines (LCL) (Figure 1A). 
High expression of OX40L in LCL was validated by RT-PCR 
(Figure 1B). All analyzed LCL expressed OX40L. In contrast, no 
expression of OX40L was detectable in the B-cell leukemia cell 
line NALM6 (Figure  1B). Primer combination 1 amplifies the 
complete open reading frame of OX40L. The amplificate from 
LCL with this primer combination was eluted from agarose 
gels and cloned into vector pIRES2-eGFP. Functionality of the 
vector was assessed by transient transfection of HEK293 cells 
(Figure  1C). Wild-type HEK293 cells are negative for OX40L 
(Figure  1A). After transfection with the OX40L-containing 
vector, HEK293 cells clearly expressed OX40L on the surface 
(Figure  1C). HEK293 cells that had been transfected with the 
empty vector were not stained with antibodies against OX40L. 
Green fluorescence of eGFP indicated that these cells were 
successfully transfected with similar efficiency as the OX40L 
transfected cells (Figure 1C).
generation of OX40l Transgenic ewing 
sarcoma cells
We transfected cells from the Ewing sarcoma cell lines A673 and 
SK-N-MC with OX40L in vector pIRES2-eGFP. Transfected cells 
were selected with geneticin sulfate and further enriched by stain-
ing with PE-labeled anti-OX40 antibodies and immunomagnetic 
beads directed at PE. After magnet-activated cell sorting 
(MACS), more than 80% of the cells expressed eGFP and OX40L 
(Figure 2A). For immunotherapy with transgenic tumor cells, it 
is necessary that the tumor cells can be irradiated without func-
tional impairments. Therefore, we tested the stability of OX40L 
after irradiation. As shown in Figure 2B, OX40L remained stable 
after irradiation for at least 5 days. Another prerequisite of trans-
genic tumor cells for immunotherapy is the stability of tumor 
antigen expression in these cells. We tested the presence of Ewing 
sarcoma-associated transcripts in the transgenic cells. OX40L 
transgenic Ewing sarcoma cells showed the same gene expression 
pattern as wild-type cells or mock-transfected cells (Figure 3). 
In contrast to wild-type cells, OX40L transgenic cells and mock 
transgenic cells expressed transcripts for the vector marker eGFP 
and the NeoR. Importantly, transgenic Ewing sarcoma cells 
stably expressed the Ewing sarcoma-specific oncofusion protein 
EWS-FLI1 (Figure 3). Other genes typically expressed in Ewing 
sarcoma cells that remained stably expressed after transfection 
included the putative cancer/testis antigen LIPI (4, 5), LIPH (46), 
the surface glycoprotein CD99 (47), cyclin D1 [CCND1 (4, 48)], 
janus kinase 1 [JAK1 (4)], and the retinoic acid metabolizing 
cytochrome P450 member 26B1 [CYP26B1 (4, 49)] (Figure 3).
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assessment of the immunostimulatory 
activity of OX40l Transgenic ewing 
sarcoma cells
For the following experiments, we used A673 Ewing sarcoma 
cells with the partial HLA type A1,A2 for which HLA-matched 
PBMCs are easily available (9, 10). HLA-matched (HLA-A1,A2 
positive) PBMCs were stimulated with A673 cells in the pres-
ence or absence of OX40L transgenic cells, interleukin 2, and 
antibodies against CD137 or 4-1BBL transgenic A673 cells. 
Reactivity of the primed cells against wild-type A673 cells was 
assessed by ELISPOT analysis (Figure  4). As expected (9, 10), 
the presence of interleukin 2 increased the number of cells that 
reacted with the sarcoma cells. In combination with interleukin 2, 
FigUre 1 | expression pattern and cloning of OX40l. (a) DNA microarray data from a panel of cell lines and normal PBMCs were analyzed for expression of 
OX40L. Presented is a heat map of OX40L signal intensities form EFT cell lines, HEK293 cells, neuroblastoma (NB) cell lines, acute lymphoid (ALL) and myeloid 
(AML) leukemia cell lines, Hodgkin’s lymphoma (HL) cell lines, lymphoblastoid cell lines (LCL), and normal PBMCs. Red and yellow correspond to high signal 
intensities and blue corresponds to low signal intensities. From left to right, the following cell lines are shown: A673 (two samples), SK-N-MC, SBSR-AKS (38) (two 
samples), HEK293 (two samples), CHP-126 (two samples), SiMa, SH-SY5Y (three samples), RPMI, Loucy, Karpas, CALL2, 697, NALM6, U937, Kasumi, KG1, 
HL60, SKNO, L-428, HD-MyZ, KM-H2, HDLM-2, L-1236 (three samples), L-540 (two samples), 11 independent LCL, and four independent PBMC samples. 
(B) Expression of OX40L was analyzed by RT-PCR in three LCL and NALM6 ALL cells. Two different primer combinations were used. ntc = no template control. 
(c) After amplification of OX40L with primer combination 1 (see Materials and Methods), PCR products from LCL were cloned into vector pIRES2-eGFP. 
Functionality of the vector was assessed by transfection of HEK293 cell. Empty pIRES2-eGFP without OX40L (Mock) served as control. Transfected cells were 
stained with anti-OX40L-PE antibodies and analyzed by flow cytometry. eGFP served as marker for transfected cells.
OX40L-transfected A673 cells marginally increased the reactivity 
of the primed cells compared to mock-transfected cells. Addition 
of antibodies against CD137 enhanced this effect significantly. 
In the presence of interleukin 2, the combination of anti-CD137 
stimulation and OX40L transfected cells showed significantly 
enhanced immune stimulation in comparison to anti-CD137 
antibodies or OX40L-transfected cells alone. The combination 
of OX40L transgenic cells with 4-1BBL transgenic cells showed 
a trend for higher stimulatory activity compared to 4-1BBL 
transgenic cells alone (Figure 4). After priming in the presence of 
OX40L transgenic A673 cells, the cells showed a higher specificity 
for A673 cells than for SK-N-MC cells or the neuroblastoma cell 
line SH-SY5Y (Figure 5).
FigUre 2 | generation of OX40l transgenic eFT cells. (a) A673 EFT cells were transfected with OX40L in vector pIRES2-eGFP. Transfected cells were stained 
with anti-OX40L-PE antibodies and analyzed by flow cytometry. eGFP served as marker for transfected cells. Transgenic cells were enriched by using anti-PE-
microbeads. After enrichment, nearly all cells stained positive for OX40L (dark blue line) and eGFP (green line). (B) A673 EFT cells were irradiated with 30 Gy and 
cultured for 5 days. Stability of OX40L expression after irradiation was assessed by staining with anti-OX40L-PE antibodies and flow cytometry.
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DiscUssiOn
The role of cancer immunotherapy that boosts the extraordinary 
power of our immune system to detect and destroy cancer cells 
still remains unclear. Acquired adaptive cancer immunotherapy 
regimens represent the most promising new treatment strategies, 
which have the ability to detect and kill cancer cells specifically 
and which have the potential to achieve a long-lasting antitumor 
response. Although tumor cells express tumor-specific antigens 
that can be recognized and targeted by T cells, the tumor pro-
duces different molecular and cellular mechanisms that reduce 
the ability of the immune system to recognize or kill tumor cells 
(50). There are many different mechanisms in the tumor micro-
environment that suppress ongoing T-cell functions and enable 
tumor escape (51, 52). For instance, the tumor microenvironment 
can reduce activation of T cells, tumor cells can escape immune 
recognition by downregulation of tumor-associated antigens or 
antigen-presenting HLA molecules, tumor cells can produce 
antigen-loss variants, tumor cells can secrete immunosuppressive 
factors (e.g., indoleamine-2,3-dioxygenase), and co-stimulatory 
signals can be absent from antigen-presenting cells (53–57). 
Naive T cells require a strong interaction between the T-cell 
receptor and antigen-presenting HLA molecules (signal 1) and 
binding of co-stimulatory molecules expressed on the surface of 
antigen-presenting cells (signal 2) for optimal activation (58). In 
the absence of a co-stimulatory signal, T cells typically enter a 
state of anergy or paralysis (59). Some members of the TNFRSF 
have been identified as co-stimulatory molecules that augment 
antitumor immune responses. Activation of these surface recep-
tors by their natural ligands or by agonistic antibodies leads to 
different cellular responses ranged from cell differentiation, 
proliferation, apoptosis, and survival to enhanced production of 
cytokines and chemokines (11, 13, 15, 16). The expression of the 
TNFRSF molecules on cells of the immune system has made these 
FigUre 4 | elisPOT analysis of PBMcs after stimulation with a673 
eFT cells. HLA-matched PBMCs were incubated together with A673 EFT 
cells in combination with the indicated immune stimuli. After 6 days, reactivity 
against A673 wild-type cells was assessed by interferon gamma ELISPOT 
analysis. The highest numbers of spots were obtained after stimulation with 
the combination of OX40L transgenic and 4-1BBL transgenic cells. 
Presented are means and standard deviations from triplicates from a 
representative experiment (N = 3). Asterisks indicate statistical significance 
(*p < 0.05; **p < 0.01; Student’s t-test).
FigUre 3 | stability of eFT makers in OX40l transgenic eFT cells. 
Expression of the indicated markers was assessed by RT-PCR in cells 
without transfection (1), after transfection with empty pIRES-eGFP vector (2), 
or after transfection with OX40L in vector pIRES-eGFP (3). Actin beta (ACTB) 
served as housekeeping control. The neomycin-resistance cassette (NeoR) 
and enhanced green fluorescent protein (eGFP) served as markers for the 
presence of the vector in the cells. Transfected and wild-type Ewing sarcoma 
cells expressed the Ewing sarcoma-specific EWS-FLI1 oncofusion transcripts 
as well as the Ewing sarcoma-associated factors lipase I (LIPI), lipase H 
(LIPH), CD99, cyclin D1 (CCND1), janus kinase 1 (JAK1), and cytochrome 
P450 family member 26B1 (CYP26B1).
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molecules as ideal targets for new immune therapy strategies (14, 
15). OX40 (CD134) and CD137 (4-1BB) and their ligands OX40L 
(CD252) and 4-1BBL are examples of such co-stimulatory effec-
tive molecules.
We have shown in previous studies that transgenic expression 
of IL-2 on EFT cells enhances the immunostimulatory activity 
but could not completely inhibit the growth of the tumor cells 
(8, 9). Addition of transgenically expressed co-stimulatory mol-
ecules on the surface of tumor cells or stimulation with agonistic 
antibody against the co-stimulatory receptor may enhance the 
cytotoxic effect of activated T cells (10, 60). In the present study, 
we present preliminary data that OX40L transgenic EFT cells not 
only preserve expression of typical Ewing sarcoma-associated 
antigens but also might enhance the immune response against 
EFT cells in combination with IL-2 and stimulation of CD137.
The presence of OX40-positive T cells at sites of tumor metasta-
ses suggests that engagement of OX40 by OX40L or agonistic anti-
bodies may enhance function of tumor-reactive T cells. In various 
studies, different tumor cells transfected with OX40L were used as 
vaccines to induce tumor-specific antitumor immunity [for review, 
see Ref. (14, 15, 61)]. Andarini et al. treated subcutaneous tumors 
of melanoma, Lewis lung carcinoma, and adenocarcinoma with 
intratumoral injection of tumor cells expressing mouse OX40L 
(62). It was shown that the treatment of tumor-bearing mice with 
tumor cells expressing OX40L induced significant suppression of 
tumor growth and enhanced survival of the treated mice (21). 
Similar results were found with EL4 lymphoma cells or with C26 
colon carcinoma cells in combination with stimulation of APC 
function with granulocyte–monocyte colony-stimulating factor 
[GM-CSF (15)]. In all these experiments, both CD4-positive 
and CD8-positive T cells were required for the induction of 
antitumor immunity and both CD4-positive and CD8-positive 
tumor-infiltrating T cells (TILs) expressed OX40. Nevertheless, it 
was unclear whether OX40-mediated signaling in CD8-positive 
T cells might have been required to induce their cytotoxic effector 
function (21). It is possible that activation of the OX40 receptor 
increases the function of tumor-specific CD4-positive T cell and 
allows more efficient effector function as well as the generation 
of CD8-positive T-cell memory (63, 64). Furthermore, in several 
preclinical models, treatment of tumor-bearing hosts with anti-
OX40 agonistic antibodies or OX40L-Fc fusion protein resulted 
in a significant tumor regression [for review, see Ref. (21)]. In 
these studies, it was suggested that activation of OX40 receptor 
by agonistic antibody or OX40L transgenic tumor cells pushes 
regulatory T cells (Treg) in suppressing or depletion depending 
on the context of simulation and the cytokine milieu (65). This 
activation of OX40 on different T cells with agonistic antibody 
or OX40L-expressing tumor cells may lead to decreased inhibi-
tory effects mediated by Treg cells and thereby might promote 
antitumor responses of CD8-positive T cell which is necessary 
to maintain long-term antitumor responses. It is possible that 
several different mechanisms are important for the antitumor 
FigUre 5 | specificity of the induced immune response. HLA-matched 
PBMCs were incubated together with A673 EFT cells in combination with the 
indicated immune stimuli. After 6 days, reactivity against the indicated 
wild-type cell lines was assessed by interferon gamma ELISPOT analysis. 
The highest numbers of spots were obtained after restimulation of A673/
anti-CD137/OX40L-primed cells with A673 cells. Presented are means and 
standard deviations from triplicates from a representative experiment (N = 3). 
Asterisks indicate statistical significance (p < 0.05; Student’s t-test).
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effects mediated through the activation of the OX40 receptor on 
T cells (61).
It is unlikely that the use of only one co-stimulatory molecule 
will be sufficient for generating immunotherapy strategies to cure 
patients with different tumor types. However, the use of combina-
tions of several co-stimulatory molecules may be a more effective 
strategy for producing immunotherapy against cancer. In this 
context, Cuadros et al. showed a potential benefit of anti-CD137 
and anti-OX40 antibodies in enhancing the immune responses 
in combination with dendritic cell-based vaccines in a Her-2/neu 
tumor model. The authors showed that joint co-stimulation with 
anti-CD137 and anti-OX40 agonistic antibodies induce strong 
effector immune responses depending on both CD4-positive 
and CD8-positive T cells (66). The combination of activation of 
two co-stimulatory molecules induces a strong effector immune 
response by primary CD8-positive T cells that is sufficient to 
attack established tumors, induce CD4-positive T-cell responses, 
and generate tumor-specific T-cell memory (66). Furthermore, 
Pan et  al. successfully treated metastatic colon carcinomas 
with anti-CD137 agonistic antibodies together with IL-12 
transfected tumor cells (67). However, the success was limited 
to small tumors. The addition of anti-OX40 agonistic antibod-
ies to the immunotherapy protocol improved the success also 
to greater tumors on established colon carcinomas. This triple 
co-stimulatory combination therapy induced a high CTL activity 
in the TILs against parenteral tumors, and this effect was partly 
cell dependent on CD4-positive T cells. These observations sug-
gested that anti-OX40 antibodies enhanced the helper function 
of CD4-positive T cells that increased the number or activity of 
CD8-positive T cells against the tumors (67).
We have shown that OX40L-expressing Ewing sarcoma cells 
preserved the expression of typical Ewing sarcoma-associated 
antigens and are practicable for immunotherapy protocols with 
transgenic tumor cells. The stimulated PBMCs exerted some 
specificity for the tumor cells that were used for stimulation. It 
remains unclear which antigens are recognized and which cell 
types are responsible for the effects. In our previous investigations, 
we observed activation of T and NK cells by IL-2 transgenic Ewing 
sarcoma cells (9). The high sensitivity of Ewing sarcoma cells for NK 
cell-mediated lysis (68, 69) might also be responsible for the higher 
“specificity” of Ewing sarcoma-activated PBMCs for these stimula-
tory cells. Whether antigenic peptides in combination with major 
histocompatibility complex (MHC) molecules are recognized by T 
cells or whether activated NK cells are triggered by receptors like 
CD226 or CD314 requires further investigations. Our data sug-
gest that OX40L-expressing tumor cells might enhance immune 
response against Ewing sarcoma cells in combination with IL-2 
and activation of the CD137/4-1BBL co-stimulatory pathway. The 
inclusion of the OX40/OX40L pathway in co-stimulation immu-
notherapy protocols might improve the immunotherapy strategies 
against Ewing sarcoma or the development of tumor vaccines.
acKnOWleDgMenTs
We thank R. Mittler for the kind gift of anti-CD137 antibodies.
reFerences
1. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, et al. Allogeneic 
and autologous stem-cell transplantation in advanced Ewing tumors. An 
update after long-term follow-up from two centers of the European Intergroup 
study EICESS. Stem-Cell Transplant Programs at Düsseldorf University 
Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann 
Oncol (2000) 11:1451–62. 
2. Staege MS, Max D. Genetics and epigenetics of the TET-ETS translocation 
network. Genet Epigenet (2009) 2:1–15. 
3. Pfeifle C, Reinhardt K, Heins S, Burdach S, Staege MS. Development and 
characterization of HAT-sensitive Ewing tumour cells for immunotherapy. 
Anticancer Res (2009) 29:4489–96. 
4. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, et al. DNA 
microarrays reveal relationship of Ewing family tumors to both endothelial 
and fetal neural crest-derived cells and define novel targets. Cancer Res (2004) 
64:8213–21. doi:10.1158/0008-5472.CAN-03-4059 
5. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS. Membrane-
associated phospholipase A1 beta (LIPI) is an Ewing tumour-associated 
cancer/testis antigen. Pediatr Blood Cancer (2008) 51:228–34. doi:10.1002/
pbc.21602 
6. Max D, Hesse M, Volkmer I, Staege MS. High expression of the 
evolutionarily conserved alpha/beta hydrolase domain contain-
ing 6 (ABHD6) in Ewing tumors. Cancer Sci (2009) 100:2383–9. 
doi:10.1111/j.1349-7006.2009.01347.x 
7. Mahlendorf DE, Staege MS. Characterization of Ewing sarcoma associated 
cancer/testis antigens. Cancer Biol Ther (2013) 14:254–61. doi:10.4161/
cbt.23298 
8. Staege MS, Gorelov V, Bulankin A, Fischer U, Dumon K, Hohndorf L, et al. 
Stable transgenic expression of IL-2 and HSV1-tk by single and fusion tumor 
October 2015 | Volume 5 | Article 2428
Reuter et al. OX40 ligand and Ewing sarcoma
Frontiers in Oncology | www.frontiersin.org
cell lines bearing EWS/FLI-1 chimeric genes. Pediatr Hematol Oncol (2003) 
20:119–40. doi:10.1080/0880010390158612 
9. Staege MS, Hansen G, Baersch G, Burdach S. Functional and molecular char-
acterization of interleukin-2 transgenic Ewing tumor cells for in vivo immu-
notherapy. Pediatr Blood Cancer (2004) 43:23–34. doi:10.1002/pbc.20013 
10. Max D, Kühnöl CD, Burdach S, Niu L, Staege MS, Föll JL. Indoleamine-2,3-
dioxygenase in an immunotherapy model for Ewing sarcoma. Anticancer Res 
(2014) 34:6431–41. 
11. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotox-
in-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U 
S A (1975) 72:3666–70. doi:10.1073/pnas.72.9.3666 
12. Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer 
research: a historical perspective. Pharmacol Ther (1994) 64:529–64. 
doi:10.1016/0163-7258(94)90023-X 
13. Croft M. The TNF family in T cell differentiation and function  –  unan-
swered questions and future directions. Semin Immunol (2014) 26:183–90. 
doi:10.1016/j.smim.2014.02.005 
14. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 
4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 
(2013) 25:230–7. doi:10.1016/j.coi.2013.01.004 
15. Foell J, Hewes B, Mittler RS. T cell costimulatory and inhibitory receptors 
as therapeutic targets for inducing anti-tumor immunity. Curr Cancer Drug 
Targets (2007) 7:55–70. doi:10.2174/156800907780006841 
16. Mittler RS, Foell J, McCausland M, Strahotin S, Niu L, Bapat A, et al. Anti-
CD137antibodies in the treatment of autoimmune disease and cancer. 
Immunol Res (2004) 29:197–208. doi:10.1385/IR:29:1-3:197 
17. Watts TH. TNF/TNFR family members in costimulation of T cell 
responses. Annu Rev Immunol (2005) 23:23–68. doi:10.1146/annurev.
immunol.23.021704.115839 
18. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. 
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate 
established tumors. Nat Med (1997) 3:682–5. doi:10.1038/nm0697-682 
19. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, et  al. 
Provision of antigen and CD137 signaling breaks immunological ignorance, 
promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 
109:651–9. doi:10.1172/JCI0214184 
20. Paterson DJ, Jefferies WA, Green JR, Brandon MR, Corthesy P, Puklavec M, 
et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 
Mr detected only on CD4 positive T blasts. Mol Immunol (1987) 24:1281–90. 
doi:10.1016/0161-5890(87)90122-2 
21. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector 
T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 4:420–31. 
doi:10.1038/nri1371 
22. Taraban VY, Rowley TF, O’Brien L, Chan HT, Haswell LE, Green MH, 
et al. Expression and costimulatory effects of the TNF receptor superfamily 
members CD134 (OX40) and CD137 (4-1BB), and their role in the gener-
ation of anti-tumor immune responses. Eur J Immunol (2002) 32:3617–27. 
doi:10.1002/1521-4141(200212)32:12<3617::AID-IMMU3617>3.0.CO;2-M 
23. Weinberg AD, Vella AT, Croft M. OX-40: life beyond the effector T cell stage. 
Semin Immunol (1998) 10:471–80. doi:10.1006/smim.1998.0146 
24. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. Costimulation of 
CD8 T cell responses by OX40. J Immunol (2004) 172:4821–5. doi:10.4049/
jimmunol.172.8.4821 
25. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell 
immunity? Nat Rev Immunol (2003) 3:609–20. doi:10.1038/nri1148 
26. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement 
in the pathology of malignant lymphomas. Blood (1995) 85:3378–404. 
27. Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG. Identification 
of a human OX-40 ligand, a costimulator of CD4+ T cells with homology 
to tumor necrosis factor. J Exp Med (1994) 180:757–62. doi:10.1084/
jem.180.2.757 
28. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent 
costimulatory molecule for sustaining primary CD4 T cell responses. 
J Immunol (1998) 161:6510–7. 
29. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. 
Expression and function of OX40 ligand on human dendritic cells. J Immunol 
(1997) 159:3838–48. 
30. Miura S, Ohtani K, Numata N, Niki M, Ohbo K, Ina Y, et al. Molecular cloning 
and characterization of a novel glycoprotein, gp34, that is specifically induced 
by the human T-cell leukemia virus type I transactivator p40 tax. Mol Cell Biol 
(1991) 11:1313–25. doi:10.1128/MCB.11.3.1313 
31. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, et al. Impairment 
of antigen-presenting cell function in mice lacking expression of OX40 ligand. 
J Exp Med (2000) 191:365–74. doi:10.1084/jem.191.2.365 
32. Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, et  al. The 
human OX40/gp34 system directly mediates adhesion of activated T cells 
to vascular endothelial cells. J Exp Med (1996) 183:2185–95. doi:10.1084/
jem.183.5.2185 
33. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL 
and Bcl-2 expression and is essential for long-term survival of CD4 T cells. 
Immunity (2001) 15:445–55. doi:10.1016/S1074-7613(01)00191-1 
34. Prell RA, Evans DE, Thalhofer C, Shi T, Funatake C, Weinberg AD. OX40-
mediated memory T cell generation is TNF receptor-associated factor 2 depen-
dent. J Immunol (2003) 171:5997–6005. doi:10.4049/jimmunol.171.11.5997 
35. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, et  al. 
Engagement of the OX-40 receptor in  vivo enhances antitumor immunity. 
J Immunol (2000) 164:2160–9. doi:10.4049/jimmunol.164.4.2160 
36. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic 
efficacy of OX-40 receptor antibody depends on tumor immunogenicity and 
anatomic site of tumor growth. Cancer Res (2000) 60:5514–21. 
37. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray 
data. Bioinformatics (2002) 18:207–8. doi:10.1093/bioinformatics/18.1.207 
38. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, et al. 
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis block-
ing endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S 
A (2009) 106:5324–9. doi:10.1073/pnas.0810759106 
39. Hutter C, Burdach S, Staege MS. Characterization of EWS/Fli-1 induced gene 
expression profiles in HEK293 cells. Klin Padiatr (2003) 215:193. 
40. Wernicke CM, Richter GH, Beinvogl BC, Plehm S, Schlitter AM, Bandapalli 
OR, et al. MondoA is highly overexpressed in acute lymphoblastic leukemia 
cells and modulates their metabolism, differentiation and survival. Leuk Res 
(2012) 36:1185–92. doi:10.1016/j.leukres.2012.05.009 
41. Metzler M, Staege MS, Harder L, Mendelova D, Zuna J, Fronkova E, et  al. 
Inv(11)(q21q23) fuses MLL to the Notch co-activator mastermind-like 2 in 
secondary T-cell acute lymphoblastic leukemia. Leukemia (2008) 22:1807–11. 
doi:10.1038/leu.2008.50 
42. Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, et al. Transcriptional 
upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-
ETO. Haematologica (2008) 93:1728–33. doi:10.3324/haematol.13044 
43. Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, 
Richter G, et al. Gene expression profiles of Hodgkin’s lymphoma cell lines 
with different sensitivity to cytotoxic drugs. Exp Hematol (2008) 36:886–96. 
doi:10.1016/j.exphem.2008.02.014 
44. Hoennscheidt C, Max D, Richter N, Staege MS. Expression of CD4 on 
Epstein-Barr virus-immortalized B cells. Scand J Immunol (2009) 70:216–25. 
doi:10.1111/j.1365-3083.2009.02286.x 
45. Foell JL, Volkmer I, Giersberg C, Kornhuber M, Horneff G, Staege MS. Loss of 
detectability of Charcot-Leyden crystal protein transcripts in blood cells after 
treatment with dimethyl sulfoxide. J Immunol Methods (2008) 339:99–103. 
doi:10.1016/j.jim.2008.08.006 
46. Hesse M, Willscher E, Schmiedel BJ, Posch S, Golbik RP, Staege MS. Sequence 
and expression of the chicken membrane-associated phospholipases A1 
alpha (LIPH) and beta (LIPI). Mol Biol Rep (2012) 39:761–9. doi:10.1007/
s11033-011-0796-0 
47. Kovar H, Dworzak M, Strehl S, Schnell E, Ambros IM, Ambros PF, et  al. 
Overexpression of the pseudoautosomal gene MIC2 in Ewing’s sarcoma and 
peripheral primitive neuroectodermal tumor. Oncogene (1990) 5:1067–70. 
48. Matsumoto Y, Tanaka K, Nakatani F, Matsunobu T, Matsuda S, Iwamoto 
Y. Downregulation and forced expression of EWS-Fli1 fusion gene results 
in changes in the expression of G(1)regulatory genes. Br J Cancer (2001) 
84:768–75. doi:10.1054/bjoc.2000.1652 
49. Staege MS, Hattenhorst UE, Neumann UE, Hutter C, Foja S, Burdach S. DNA-
microarrays as tools for the identification of tumor specific gene expression 
profiles: applications in tumor biology, diagnosis and therapy. Klin Padiatr 
(2003) 215:135–9. doi:10.1055/s-2003-39371 
50. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor 
antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 12:337–65. 
doi:10.1146/annurev.iy.12.040194.002005 
October 2015 | Volume 5 | Article 2429
Reuter et al. OX40 ligand and Ewing sarcoma
Frontiers in Oncology | www.frontiersin.org
51. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints con-
trolling antitumor immunity and their blockade in the development of cancer 
immunotherapeutics and vaccines. Oncogene (2014) 33:4623–31. doi:10.1038/
onc.2013.432 
52. Crespo J, Sun H, Welling TH, Tian Z, Zou WT. Cell anergy, exhaustion, senes-
cence, and stemness in the tumor microenvironment. Curr Opin Immunol 
(2013) 25:214–21. doi:10.1016/j.coi.2012.12.003 
53. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated 
signaling costimulates murine T cells and prevents induction of anergy in 
T-cell clones. Nature (1992) 356:607–9. doi:10.1038/356607a0 
54. Davis ID. An overview of cancer immunotherapy. Immunol Cell Biol (2000) 
78:179–95. doi:10.1046/j.1440-1711.2000.00906.x 
55. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 
(1995) 82:13–7. doi:10.1016/0092-8674(95)90047-0 
56. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after 
nearly complete rejection is due to antigen-loss variants rather than immu-
nosuppression. J Exp Med (1983) 157:1040–52. doi:10.1084/jem.157.3.1040 
57. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-
Keen M, et  al. Implications for immunosurveillance of altered HLA class I 
phenotypes in human tumours. Immunol Today (1997) 18:89–95. doi:10.1016/
S0167-5699(96)10075-X 
58. Ochoa AC, Longo DL. Alteration of signal transduction in T cells from cancer 
patients. Important Adv Oncol (1995) 1995:43–54. 
59. Lafferty KJ, Gill RG. The maintenance of self-tolerance. Immunol Cell Biol 
(1993) 71:209–14. doi:10.1038/icb.1993.23 
60. Kühnöl C, Herbarth M, Föll J, Staege MS, Kramm C. CD137 stimulation 
and p38 MAPK inhibition improve reactivity in an in  vitro model of glio-
blastoma immunotherapy. Cancer Immunol Immunother (2013) 62:1797–809. 
doi:10.1007/s00262-013-1484-9 
61. Linch SN, McNamara MJ, Redmond LW. OX40 agonists and combination 
immunotherapy: putting the pedal to the metal. Front Oncol (2015) 5:34. 
doi:10.3389/fonc.2015.00034 
62. Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S, et al. 
Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor 
cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res (2004) 
64:3281–7. doi:10.1158/0008-5472.CAN-03-3911 
63. Weinberg AD. OX40: targeted immunotherapy – implications for tempering 
autoimmunity and enhancing vaccines. Trends Immunol (2002) 23:102–9. 
doi:10.1016/S1471-4906(01)02127-5 
64. Ali SA, Ahmad M, Lynam J, McLean CS, Entwisle C, Loudon P, et al. Anti-
tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 
(2004) 22:3585–94. doi:10.1016/j.vaccine.2004.03.041 
65. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression 
by regulatory T cells and facilitates tumor rejection. J Exp Med (2008) 
204:825–39. doi:10.1084/jem.20071341 
66. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P, et al. 
Vaccination with dendritic cells pulsed with apoptotic tumors in combination 
with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-medi-
ated protective immunity in Her-2/neu transgenic mice. Int J Cancer (2005) 
116:934–43. doi:10.1002/ijc.21098 
67. Pan PY, Zang Y, Weber K, Meseck ML, Chen SH. OX40 ligation enhances 
primary and memory cytotoxic T lymphocyte responses in an immunother-
apy for hepatic colon metastases. Mol Ther (2002) 6:528–36. doi:10.1006/
mthe.2002.0699 
68. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, 
Gelderblom H, et al. NK cells recognize and lyse Ewing sarcoma cells through 
NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 
45:3917–25. doi:10.1016/j.molimm.2008.06.016 
69. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. 
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin 
Cancer Res (2010) 16:3901–9. doi:10.1158/1078-0432.CCR-10-0735 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Reuter, Staege, Kühnöl and Föll. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
